Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Peptide Receptor Radionuclide Therapy”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Ended earlyNCT04023331
What this trial is testing

67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk, Relapsed, Refractory Neuroblastoma

Who this might be right for
NeuroblastomaRelapsed NeuroblastomaRefractory Neuroblastoma
Clarity Pharmaceuticals Ltd 21
Early research (Phase 1)UnknownNCT06081322
What this trial is testing

Evaluate the Safety and Efficacy of PRRT With 177Lu-EB-FAPI in Patients With Advanced Cholopancreatic Tumors

Who this might be right for
Advanced Pancreatic Cancer and Cholangiocarcinoma
Zhejiang University 29
Testing effectiveness (Phase 2)UnknownNCT04194125
What this trial is testing

Personalized CAPTEM Radiopeptide Therapy of Advanced, Non-resectable Neuroendocrine Cancer

Who this might be right for
Neuroendocrine Tumors
University of Warmia and Mazury 25
Testing effectiveness (Phase 2)Ended earlyNCT05568017
What this trial is testing

Neoadjuvant PRRT With Y-90-DOTATOC in pNET

Who this might be right for
Pancreatic Neuroendocrine Tumor
European Institute of Oncology 11
Testing effectiveness (Phase 2)Looking for participantsNCT05583708
What this trial is testing

Phase II Study of Peptide Receptor Radionuclide Therapy in Combination With Immunotherapy for Patients With Merkel Cell Cancer

Who this might be right for
Merkel Cell Carcinoma
Weill Medical College of Cornell University 18
Not applicableStudy completedNCT02125474
What this trial is testing

Efficacy of 177-Lu-DOTA 0, Tyr 3 Octreotate

Who this might be right for
Neuroendocrine Tumors
Instituto Nacional de Cancerologia, Columbia 39
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06121271
What this trial is testing

Trial of Lu-177 DOTATATE (Lutathera®) in Unlicensed Indications

Who this might be right for
Bronchial and Thymic Neuroendocrine TumourParaganglioma/ PhaeochromocytomaMedullary Thyroid Carcinoma+1 more
University College, London 110
Testing effectiveness (Phase 2)WithdrawnNCT03013387
What this trial is testing

Dosimetry Guided PRRT With 90Y-DOTATOC

Who this might be right for
Neuroendrocrine TumorsMeningiomaNeuroblastoma+1 more
Sue O'Dorisio
Not applicableStudy completedNCT05785663
What this trial is testing

AminoMedixTM for Kidney Protection During Radionuclide Therapy

Who this might be right for
Radiation Nephropathy
Excel Diagnostics and Nuclear Oncology Center 28
Not applicableLooking for participantsNCT06500065
What this trial is testing

68Ga-DOTATATE PET/CT for the Diagnosis of Soft Tissue Sarcomas

Who this might be right for
Soft Tissue Sarcoma
Ohio State University Comprehensive Cancer Center 30
Large-scale testing (Phase 3)Looking for participantsNCT05918302
What this trial is testing

Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.

Who this might be right for
Neuroendocrine TumorsLung Neuroendocrine NeoplasmThymus Neoplasms
Grupo Espanol de Tumores Neuroendocrinos 170
Large-scale testing (Phase 3)Looking for participantsNCT06855095
What this trial is testing

Absorbed Tumor Dose in Peptide Receptor Radionuclide Therapy with Long-acting Somatostatin Analogues - ATSA Trial

Who this might be right for
Neuroendocrine TumorsNeuroendocrine Tumor Grade 1Neuroendocrine Tumor Grade 2+1 more
The Netherlands Cancer Institute 39
Testing effectiveness (Phase 2)Study completedNCT04385992
What this trial is testing

Neoadjuvant PRRT With 177Lu-DOTATATE Followed by Surgery for Resectable PanNET

Who this might be right for
Neuroendocrine Tumors
IRCCS San Raffaele 31
Large-scale testing (Phase 3)Not Yet RecruitingNCT07842172
What this trial is testing

Somatostatin Analogues vs. Observation After Peptide Receptor Radionuclide Therapy (PRRT) in Nonfunctional Neuroendocrine Neoplasms

Who this might be right for
Neuroendocrine NeoplasmGastroenteropancreatic Neuroendocrine Neoplasm
Washington University School of Medicine 240
Testing effectiveness (Phase 2)Ended earlyNCT02488512
What this trial is testing

Peptide Receptor Radionuclide Therapy With 90Y-Dotatoc in Relapsed/Refractory Diffuse Large B Cell and Mantle Cell Lymphomas

Who this might be right for
DLBCLMCLRecurrent Disease
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS 1
Testing effectiveness (Phase 2)Looking for participantsNCT04837885
What this trial is testing

Intra-arterial Hepatic (IAH) Infusion of Radiolabelled Somatostatin Analogs in GEP-NET Patients With Dominant Liver Metastases

Who this might be right for
Neuroendocrine TumorLiver MetastasesNeuroendocrine Gastroenteropancreatic Tumour
University Hospital, Bordeaux 23
Post-approval studies (Phase 4)Study completedNCT04524442
What this trial is testing

Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients

Who this might be right for
Gastroenteropancreatic Neuroendocrine Tumors
Advanced Accelerator Applications 42
Testing effectiveness (Phase 2)Looking for participantsNCT04997317
What this trial is testing

Treatment of Recurrent or Progressive Meningiomas With the Radiolabelled Somatostatin Antagonist 177Lu-satoreotide

Who this might be right for
Meningioma
University Hospital, Basel, Switzerland 18
Testing effectiveness (Phase 2)Looking for participantsNCT04917484
What this trial is testing

Dosimetry Based PRRT Versus Standard Dose PRRT With Lu-177-DOTATOC in NEN Patients

Who this might be right for
Neuroendocrine Neoplasm
Tine Gregersen, MD 100
Testing effectiveness (Phase 2)WithdrawnNCT03923257
What this trial is testing

Dosimetry Guided PRRT With 177Lu-DOTATATE in Children and Adolescents

Who this might be right for
Neuroendocrine TumorsPheochromocytomaParaganglioma
Sue O'Dorisio
Next Page